Experimental drug tested for rare blood diseases
NCT ID NCT05086744
Summary
This study tested an oral drug called iptacopan in people with two autoimmune blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The main goal was to see if the drug could safely improve blood counts (platelets for ITP, hemoglobin for CAD) over a 12-week treatment period. Participants who responded well could continue treatment for up to two additional years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Milan, MI, 20122, Italy
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Murcia, 30008, Spain
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.